Logo image of ALPHI.PA

FACEPHI BIOMETRIA SA (ALPHI.PA) Stock Fundamental Analysis

EPA:ALPHI - Euronext Paris - Matif - ES0105029005 - Common Stock - Currency: EUR

2.45  -0.23 (-8.58%)

Fundamental Rating

2

Overall ALPHI gets a fundamental rating of 2 out of 10. We evaluated ALPHI against 97 industry peers in the Software industry. ALPHI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ALPHI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALPHI had negative earnings in the past year.
In the past year ALPHI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ALPHI reported negative net income in multiple years.
In multiple years ALPHI reported negative operating cash flow during the last 5 years.
ALPHI.PA Yearly Net Income VS EBIT VS OCF VS FCFALPHI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M -6M -8M

1.2 Ratios

ALPHI has a worse Return On Assets (-12.82%) than 75.26% of its industry peers.
ALPHI has a worse Return On Equity (-36.38%) than 74.23% of its industry peers.
Industry RankSector Rank
ROA -12.82%
ROE -36.38%
ROIC N/A
ROA(3y)-3%
ROA(5y)-1.81%
ROE(3y)-6.86%
ROE(5y)-3.52%
ROIC(3y)N/A
ROIC(5y)N/A
ALPHI.PA Yearly ROA, ROE, ROICALPHI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Gross Margin of ALPHI (55.75%) is worse than 64.95% of its industry peers.
In the last couple of years the Gross Margin of ALPHI has declined.
ALPHI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.14%
GM growth 5Y-12.77%
ALPHI.PA Yearly Profit, Operating, Gross MarginsALPHI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100

More info and screens

1

2. Health

2.1 Basic Checks

ALPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALPHI has been increased compared to 1 year ago.
Compared to 5 years ago, ALPHI has more shares outstanding
Compared to 1 year ago, ALPHI has a worse debt to assets ratio.
ALPHI.PA Yearly Shares OutstandingALPHI.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ALPHI.PA Yearly Total Debt VS Total AssetsALPHI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 0.90, we must say that ALPHI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.90, ALPHI is doing worse than 69.07% of the companies in the same industry.
A Debt/Equity ratio of 0.12 indicates that ALPHI is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.12, ALPHI is doing good in the industry, outperforming 76.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 0.9
ROIC/WACCN/A
WACC8.49%
ALPHI.PA Yearly LT Debt VS Equity VS FCFALPHI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M 20M

2.3 Liquidity

ALPHI has a Current Ratio of 0.69. This is a bad value and indicates that ALPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
ALPHI has a worse Current ratio (0.69) than 81.44% of its industry peers.
A Quick Ratio of 0.69 indicates that ALPHI may have some problems paying its short term obligations.
ALPHI has a worse Quick ratio (0.69) than 81.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.69
Quick Ratio 0.69
ALPHI.PA Yearly Current Assets VS Current LiabilitesALPHI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALPHI have decreased strongly by -81.67% in the last year.
The Revenue has grown by 12.10% in the past year. This is quite good.
The Revenue has been growing by 41.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-81.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.78%
Revenue 1Y (TTM)12.1%
Revenue growth 3Y51.27%
Revenue growth 5Y41.2%
Sales Q2Q%19.95%

3.2 Future

ALPHI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.17% yearly.
ALPHI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.95% yearly.
EPS Next Y45%
EPS Next 2Y30.38%
EPS Next 3Y42.17%
EPS Next 5YN/A
Revenue Next Year30.08%
Revenue Next 2Y20%
Revenue Next 3Y26.98%
Revenue Next 5Y14.95%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALPHI.PA Yearly Revenue VS EstimatesALPHI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
ALPHI.PA Yearly EPS VS EstimatesALPHI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2022 2023 2024 2025 2026 0 0.1 -0.1 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALPHI. In the last year negative earnings were reported.
Also next year ALPHI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPHI.PA Price Earnings VS Forward Price EarningsALPHI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPHI.PA Per share dataALPHI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALPHI's earnings are expected to grow with 42.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.38%
EPS Next 3Y42.17%

More info and screens

0

5. Dividend

5.1 Amount

ALPHI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FACEPHI BIOMETRIA SA

EPA:ALPHI (5/9/2025, 7:00:00 PM)

2.45

-0.23 (-8.58%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)10-20 2025-10-20
Inst Owners18.62%
Inst Owner ChangeN/A
Ins Owners6.65%
Ins Owner ChangeN/A
Market Cap63.16M
Analysts82.86
Price Target1.82 (-25.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.08%
PT rev (3m)-6.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.33
P/FCF N/A
P/OCF 33.17
P/B 3.89
P/tB 15.05
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)0.07
OCFY3.01%
SpS1.05
BVpS0.63
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.82%
ROE -36.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.75%
FCFM N/A
ROA(3y)-3%
ROA(5y)-1.81%
ROE(3y)-6.86%
ROE(5y)-3.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.14%
GM growth 5Y-12.77%
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 183.54%
Cap/Sales 41.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.69
Quick Ratio 0.69
Altman-Z 0.9
F-Score3
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)169.83%
Cap/Depr(5y)192.18%
Cap/Sales(3y)22.62%
Cap/Sales(5y)21.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-81.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.78%
EPS Next Y45%
EPS Next 2Y30.38%
EPS Next 3Y42.17%
EPS Next 5YN/A
Revenue 1Y (TTM)12.1%
Revenue growth 3Y51.27%
Revenue growth 5Y41.2%
Sales Q2Q%19.95%
Revenue Next Year30.08%
Revenue Next 2Y20%
Revenue Next 3Y26.98%
Revenue Next 5Y14.95%
EBIT growth 1Y-264.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.1%
EBIT Next 3Y47.24%
EBIT Next 5Y33.39%
FCF growth 1Y-48.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y145.39%
OCF growth 3Y-15.88%
OCF growth 5Y27.63%